Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 205.00 +1.68 (+0.83%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,127,365 Open 204.50 Bid (Size) 202.00 (1) Ask (Size) 207.00 (1) Prev. Close 203.32 Today's Range 202.13 - 205.54 52wk Range 189.44 - 270.50 Shares Outstanding 144,000,000 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement August 22, 2024 The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated... Via Benzinga Cracking The Code: Understanding Analyst Reviews For Biogen August 19, 2024 Via Benzinga Performance YTD -23.42% -23.42% 1 Month -9.30% -9.30% 3 Month -5.88% -5.88% 6 Month -8.20% -8.20% 1 Year -21.88% -21.88% More News Read More New Study Reveals How Classical Music Could Revolutionize Depression Care August 12, 2024 Via PressReach Exposures Product Safety A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys. August 11, 2024 Via The Motley Fool How Is The Market Feeling About Biogen? August 09, 2024 Via Benzinga Biogen Earnings Flat; Biotech Giant Raises Guidance August 01, 2024 Via Investor's Business Daily The Analyst Verdict: Biogen In The Eyes Of 12 Experts July 29, 2024 Via Benzinga As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032 August 09, 2024 Via FinancialNewsMedia Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review August 02, 2024 Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings July 29, 2024 Via Benzinga Topics Economy Exposures Interest Rates Biogen (BIIB) Q2 2024 Earnings Call Transcript August 01, 2024 Via The Motley Fool Topics Earnings Exposures Financial US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? August 01, 2024 Via Benzinga Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales August 01, 2024 Via Benzinga Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November August 01, 2024 Via Benzinga New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) July 30, 2024 From Biogen Inc. Via GlobeNewswire Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease July 30, 2024 From Biogen Inc. Via GlobeNewswire Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy? July 29, 2024 Via The Motley Fool Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events July 26, 2024 Via Benzinga Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug July 26, 2024 Via Investor's Business Daily Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session July 26, 2024 Via Benzinga Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union July 26, 2024 From Biogen Inc. Via GlobeNewswire BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm July 25, 2024 From Bragar Eagel & Squire Via GlobeNewswire Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints July 24, 2024 Via Benzinga Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails July 24, 2024 Via Investor's Business Daily Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor July 24, 2024 From Sage Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.